Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06563414 · ClinicalTrials.gov registry record
A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)
A clinical trial of Epidermolysis Bullosa Dystrophica and Epidermolysis Bullosa Dystrophica, Recessive, sponsored by Krystal Biotech.
- Recruiting
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT06563414: Recruiting study of Epidermolysis Bullosa Dystrophica and Epidermolysis Bullosa Dystrophica, Recessive, sponsored by Krystal Biotech.
NCT06563414 is a study of Epidermolysis Bullosa Dystrophica and Epidermolysis Bullosa Dystrophica, Recessive that is actively recruiting participants, run by Krystal Biotech. The registered enrollment target is 40 participants, above the 34-participant average among 3 other Epidermolysis Bullosa Dystrophica trials with a reported enrollment target (18% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06563414, a study of Epidermolysis Bullosa Dystrophica and Epidermolysis Bullosa Dystrophica, Recessive, is actively recruiting participants, sponsored by Krystal Biotech.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a non-interventional, observational study that will evaluate the natural history of corneal abrasions in patients with Dystrophic Epidermolysis Bullosa (DEB).
Primary Outcome
Frequency of corneal abrasion symptoms
Conditions Studied
Study Locations (1)
Pennsylvania
- Krystal Biotech - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-08-02 |
| Est. Completion | 2025-12 |
What NCT06563414 shows while recruiting
NCT06563414 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, above the 34-participant average among 3 other Epidermolysis Bullosa Dystrophica trials with a reported enrollment target (18% higher).
The record links to 3 conditions, with Epidermolysis Bullosa Dystrophica appearing as the primary indexed condition, and to 0 interventions.
NCT06563414 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06563414 about?
NCT06563414 is a clinical study titled "A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)". This study is a non-interventional, observational study that will evaluate the natural history of corneal abrasions in patients with Dystrophic Epidermolysis Bullosa (DEB).
What is the current status of trial NCT06563414?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2024-08-02. Estimated completion is 2025-12.
What conditions does trial NCT06563414 study?
This clinical trial studies the following conditions: Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans.
Who is sponsoring clinical trial NCT06563414?
This trial is sponsored by Krystal Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06563414 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epidermolysis Bullosa Dystrophica
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI